ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2342

Transcriptomic Analysis Reveals Mitochondrial and Monocyte Dysfunctions Are Linked to the Interferonopathy of Juvenile Dermatomyositis

Claire Deakin1, Elizabeth Rosser1, Lucy Marshall1, Meredyth Wilkinson2, Aziza Khabbush3, Stefania Simou1, Georg Otto3, Stefanie Dowle3, Daniel Kelberman3, Simon Yona2, Simon Eaton3 and Lucy R Wedderburn1, 1Infection, Immunity and Inflammation Programme, UCL Great Ormond Street Institute of Child Health, University College London, United Kingdom, London, United Kingdom, 2Division of Medicine, University College London, London, United Kingdom, 3Genetics and Genomic Medicine Programme, UCL Great Ormond Street Institute of Child Health, University College London, United Kingdom, London, United Kingdom

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Gene Expression, juvenile dermatomyositis, Mitochondria, monocytes and pathogenesis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Pediatric Rheumatology – Pathogenesis and Genetics Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Although type I interferon (IFN1) and endoplasmic reticulum (ER) stress have been implicated in pathogenesis of juvenile dermatomyositis (JDM), little else is known about additional biological processes that may be involved and perhaps upstream of these pathways, or about processes that remain abnormal even when inflammation is controlled. To identify novel pathways dysregulated in JDM, we performed RNASeq on sorted immune subtypes from JDM patients and healthy controls.

Methods:

Peripheral blood samples were obtained from patients enrolled in the Juvenile Dermatomyositis Cohort and Biomarker Study (JDCBS) at pre-treatment (n=13) and 11.8 [11.3-13.2] months follow-up, (n=13) including n=10 matched samples, and age/sex-matched healthy controls (n=8). CD4+, CD8+, CD14+ and CD19+ cells were flow-sorted from PBMCs by flow cytometry and RNA was extracted and sequenced. Gene set enrichment analysis (GSEA) and gene ontology (GO) term enrichment analysis were performed.

Results:

A strong IFN1 signature was identified: “IFNα signaling” was the most strongly enriched gene set identified by GSEA in all cell types (normalized enrichment scores of 2.39 (p<0.001), 2.84 (p<0.001), 2.88 (p<0.001) and 3.41 (p<0.001) for CD4, CD8, CD19 and CD14 cells, respectively). Overall, a higher proportion of differentially expressed (DE) genes were identified in CD14+ monocytes compared to other cell subtypes. Interestingly, 1,594 genes were DE in on-treatment monocytes compared to controls when IFN1 was no longer abnormal, suggesting on-going abnormal function even after a year of treatment. GO analysis of these genes identified over-representation of GO terms involved in mitochondrial function. A mitochondrial score (comprising all 13 protein-coding mitochondrial genes) correlates negatively with an IFN1 score (15 representative IFN-stimulated genes) in baseline monocytes (R=-0.87, p=0.003), indicating reduced expression of mitochondrially-encoded genes is associated with increased IFN1 signature. Analysis of the 343 genes annotated by the “Mitochondrion” Gene Ontology term GO:0005739 showed 54 were DE in baseline monocytes compared to follow-up, 51 were DE in baseline monocytes compared to controls, and 59 were DE in follow-up monocytes compared to controls. Notably, a set of genes involved in mitochondrial function were abnormally expressed in both baseline and follow-up monocytes compared to controls, indicating that mitochondrial dysfunction is not fully corrected by current treatment. Functional studies to characterise dysfunctions of monocytes and mitochondria are ongoing.

Conclusion:

This transcriptomic study has identified abnormal gene expression in the monocyte compartment in particular, and a striking dysregulation of genes involved in mitochondrial function. Ongoing functional work to characterize these dysfunctions will explore the potential of mitochondrial dysfunction as a novel treatment target.


Disclosure: C. Deakin, None; E. Rosser, None; L. Marshall, None; M. Wilkinson, None; A. Khabbush, None; S. Simou, None; G. Otto, None; S. Dowle, None; D. Kelberman, None; S. Yona, None; S. Eaton, None; L. R. Wedderburn, None.

To cite this abstract in AMA style:

Deakin C, Rosser E, Marshall L, Wilkinson M, Khabbush A, Simou S, Otto G, Dowle S, Kelberman D, Yona S, Eaton S, Wedderburn LR. Transcriptomic Analysis Reveals Mitochondrial and Monocyte Dysfunctions Are Linked to the Interferonopathy of Juvenile Dermatomyositis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/transcriptomic-analysis-reveals-mitochondrial-and-monocyte-dysfunctions-are-linked-to-the-interferonopathy-of-juvenile-dermatomyositis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/transcriptomic-analysis-reveals-mitochondrial-and-monocyte-dysfunctions-are-linked-to-the-interferonopathy-of-juvenile-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology